Tarsus Pharmaceuticals: Revolutionizing Eye Care with Breakthrough Therapies, Yet Facing Typical Biotech Risks
Overview
Tarsus Pharmaceuticals, a biopharmaceutical company, is leveraging its unique positioning in eye care to serve unmet medical needs with its flagship product, XDEMVY, targeting Demodex blepharitis. Building on its U.S. launch success, Tarsus is rapidly expanding its pipeline into related therapeutic areas, positioning both XDEMVY and future products as foundational elements in creating category-defining therapies. With established insurance coverage and growing physician adoption, Tarsus is cementing its leadership in the market and exploring new sector opportunities in infectious disease prevention and beyond.